Tarzana, Calif (PRWEB) January 29, 2014
Today EntroGen (http://www.entrogen.com) announced immediate availability of its expanded colorectal cancer screening products. EntroGen K-Ras and N-Ras Mutation Analysis kits have been updated to include coverage for exon 2, 3 and 4 mutations in both genes. The Company has obtained a CE-IVD mark for these products.
The importance of mutations in exons 3 and 4 of K-Ras and 2, 3 and 4 of N-Ras were demonstrated in a randomized, multicenter phase 3 study published in 2013 (PRIME study 20050203), where researchers from Amgen identified them as markers of innate resistance to panitumumab (Vectibix®) in addition to the already known exon 2 mutations in K-Ras. Following the publication of this study, Amgen issued new guidelines for prescribing this drug for treatment of metastatic colorectal cancer.
The newly expanded real-time PCR kits now cover all known mutations in codons 12, 13, 59, 61, 117 and 146 of the K-Ras and N-Ras genes, as well as the B-Raf V600E mutation, providing a comprehensive screening tool that has superior sensitivity and turnaround time than those offered by NGS platforms. The products have been validated on various real time PCR instrument models.
About EntroGen (http://www.entrogen.com)
Based in Los Angeles, California, EntroGen is a biotechnology company with a focus on molecular diagnostic products in the areas of hematology and oncology. EntroGen has a growing commercial portfolio of real-time PCR-based tests, with many of its products being used to guide and monitor targeted therapies for various malignancies. EntroGen’s footprint reaches every corner of the globe delivering reliable clinical and research products.